| The predictive value of tumor-cell kinetic parameters in radiotherapy: considerations regarding data production and analysis |
| NH Terry and LJ Peters |
|
JCO Aug 1 1995: 1833–1836.
[PDF]
|
 |
| Curing cancer in children: minimizing price, maximizing value |
| AT Meadows |
|
JCO Aug 1 1995: 1837–1839.
[PDF]
|
|
| Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non-small-cell lung cancer or just another Elvis sighting? |
| DH Johnson and LH Einhorn |
|
JCO Aug 1 1995: 1840–1842.
[PDF]
|
|
|
In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen |
| |
R Corvo, W Giaretti, G Sanguineti, E Geido, R Orecchia, M Guenzi, G Margarino, A Bacigalupo, G Garaventa, and M Barbieri |
| |
JCO Aug 1 1995: 1843–1850.
[Abstract]
[PDF]
|
|
|
Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group |
| |
NE Breslow, JR Takashima, JA Whitton, J Moksness, GJ D'Angio, and DM Green |
| |
JCO Aug 1 1995: 1851–1859.
[Abstract]
[PDF]
|
|
|
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis |
| |
CJ Langer, JC Leighton, RL Comis, PJ O'Dwyer, CA McAleer, CA Bonjo, PF Engstrom, S Litwin, and RF Ozols |
| |
JCO Aug 1 1995: 1860–1870.
[Abstract]
[PDF]
|
|
|
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B |
| |
AA Miller, JE Herndon, 2nd, DR Hollis, J Ellerton, A Langleben, F Richards, 2nd, and MR Green |
| |
JCO Aug 1 1995: 1871–1879.
[Abstract]
[PDF]
|
|
|
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805 |
| |
KS Albain, VW Rusch, JJ Crowley, TW Rice, AT Turrisi, 3rd, JK Weick, VA Lonchyna, CA Presant, RJ McKenna, and DR Gandara |
| |
JCO Aug 1 1995: 1880–1892.
[Abstract]
[PDF]
|
|
|
Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor |
| |
JS Lee, A Yoon, SK Kalapurakal, JY Ro, JJ Lee, N Tu, WN Hittelman, and WK Hong |
| |
JCO Aug 1 1995: 1893–1903.
[Abstract]
[PDF]
|
|
|
Does knowledge guide practice? Another look at the management of non- small-cell lung cancer |
| |
B Raby, J Pater, and WJ Mackillop |
| |
JCO Aug 1 1995: 1904–1911.
[Abstract]
[PDF]
|
|
|
CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors |
| |
SA Cannistra, G Abu-Jawdeh, J Niloff, T Strobel, L Swanson, J Andersen, and C Ottensmeier |
| |
JCO Aug 1 1995: 1912–1921.
[Abstract]
[PDF]
|
|
|
Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation |
| |
MW Dercksen, S Rodenhuis, MK Dirkson, WP Schaasberg, JW Baars, E van der Wall, IC Slaper-Cortenbach, HM Pinedo, AE Von dem Borne, and CE van der Schoot |
| |
JCO Aug 1 1995: 1922–1932.
[Abstract]
[PDF]
|
|
|
Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double- blind, placebo-controlled study |
| |
JN Bavinck, LM Tieben, FJ Van der Woude, AM Tegzess, J Hermans, J ter Schegget, and BJ Vermeer |
| |
JCO Aug 1 1995: 1933–1938.
[Abstract]
[PDF]
|
|
|
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study |
| |
PS Goedegebuure, LM Douville, H Li, GC Richmond, DD Schoof, M Scavone, and TJ Eberlein |
| |
JCO Aug 1 1995: 1939–1949.
[Abstract]
[PDF]
|
|
|
Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro |
| |
RJ Motzer, L Schwartz, TM Law, BA Murphy, AD Hoffman, AP Albino, V Vlamis, and DM Nanus |
| |
JCO Aug 1 1995: 1950–1957.
[Abstract]
[PDF]
|
|
|
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma |
| |
RJ Motzer, P Lyn, P Fischer, P Lianes, RL Ngo, C Cordon-Cardo, and JP O'Brien |
| |
JCO Aug 1 1995: 1958–1965.
[Abstract]
[PDF]
|
|
|
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma |
| |
J Bailey, JM Pluda, A Foli, MW Saville, S Bauza, PC Adamson, RF Murphy, RB Cohen, S Broder, and R Yarchoan |
| |
JCO Aug 1 1995: 1966–1974.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules |
| |
EK Rowinsky, DA Noe, LB Grochow, SE Sartorious, MK Bowling, TL Chen, BG Lubejko, SH Kaufmann, and RC Donehower |
| |
JCO Aug 1 1995: 1975–1984.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy |
| |
WH Wilson, C Jamis-Dow, G Bryant, FM Balis, RW Klecker, SE Bates, BA Chabner, SM Steinberg, DR Kohler, and RE Wittes |
| |
JCO Aug 1 1995: 1985–1994.
[Abstract]
[PDF]
|
|
|
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy |
| |
WH Wilson, SE Bates, A Fojo, G Bryant, Z Zhan, J Regis, RE Wittes, ES Jaffe, SM Steinberg, and J Herdt |
| |
JCO Aug 1 1995: 1995–2004.
[Abstract]
[PDF]
|
|
|
Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B |
| |
GP Canellos, GR Petroni, M Barcos, DB Duggan, and BA Peterson |
| |
JCO Aug 1 1995: 2005–2011.
[Abstract]
[PDF]
|
|
|
Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial |
| |
TE Witzig, L Letendre, J Gerstner, G Schroeder, JA Mailliard, G Colon-Otero, RF Marschke, and HE Windschitl |
| |
JCO Aug 1 1995: 2012–2015.
[Abstract]
[PDF]
|
|
|
Second solid malignancies after combined modality therapy for Hodgkin's disease |
| |
R Doria, T Holford, LR Farber, LR Prosnitz, and DL Cooper |
| |
JCO Aug 1 1995: 2016–2022.
[Abstract]
[PDF]
|
|
|
B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: a Pediatric Oncology Group study |
| |
RE Hutchison, CW Berard, JJ Shuster, MP Link, TE Pick, and SB Murphy |
| |
JCO Aug 1 1995: 2023–2032.
[Abstract]
[PDF]
|
|
|
Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan |
| |
K Yamamoto, Y Hayashi, R Hanada, A Kikuchi, M Ichikawa, M Tanimura, and S Yoshioka |
| |
JCO Aug 1 1995: 2033–2038.
[Abstract]
[PDF]
|
|
|
Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer |
| |
SL Berg, A Tolcher, JA O'Shaughnessy, AM Denicoff, M Noone, FP Ognibene, KH Cowan, and FM Balis |
| |
JCO Aug 1 1995: 2039–2042.
[Abstract]
[PDF]
|
|
|
Prognostic factors for prolonged progression-free survival with high- dose chemotherapy with autologous stem-cell support for advanced breast cancer |
| |
LJ Ayash, C Wheeler, D Fairclough, G Schwartz, E Reich, D Warren, L Schnipper, K Antman, E Frei, 3rd, and A Elias |
| |
JCO Aug 1 1995: 2043–2049.
[Abstract]
[PDF]
|
|
|
Tandem autotransplantation for the treatment of metastatic breast cancer |
| |
ER Broun, R Sridhara, GW Sledge, D Loesch, PH Kneebone, M Hanna, R Hromas, K Cornetta, and LH Einhorn |
| |
JCO Aug 1 1995: 2050–2055.
[Abstract]
[PDF]
|
|
|
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial |
| |
JS Abrams, DA Vena, J Baltz, J Adams, M Montello, M Christian, N Onetto, S Desmond-Hellmann, R Canetta, and MA Friedman |
| |
JCO Aug 1 1995: 2056–2065.
[Abstract]
[PDF]
|
|
|
Salvage chemotherapy with paclitaxel for recurrent primary brain tumors |
| |
MC Chamberlain and P Kormanik |
| |
JCO Aug 1 1995: 2066–2071.
[Abstract]
[PDF]
|
|
|
Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide |
| |
MC Chamberlain and MR Grafe |
| |
JCO Aug 1 1995: 2072–2076.
[Abstract]
[PDF]
|
|
|
Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx |
| |
DA Fein, WR Lee, AL Hanlon, JA Ridge, CJ Langer, WJ Curran, Jr, and LR Coia |
| |
JCO Aug 1 1995: 2077–2083.
[Abstract]
[PDF]
|
|
|
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system |
| |
MM Heiss, R Babic, H Allgayer, KU Gruetzner, KW Jauch, U Loehrs, and FW Schildberg |
| |
JCO Aug 1 1995: 2084–2093.
[Abstract]
[PDF]
|
|
|
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin |
| |
JL Abbruzzese, MC Abbruzzese, R Lenzi, KR Hess, and MN Raber |
| |
JCO Aug 1 1995: 2094–2103.
[Abstract]
[PDF]
|
|
|
Role of computed tomography in the staging of patients with local- regional metastases of melanoma |
| |
AC Buzaid, L Tinoco, MI Ross, SS Legha, and RS Benjamin |
| |
JCO Aug 1 1995: 2104–2108.
[Abstract]
[PDF]
|
|
|
Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay |
| |
DS Hoon, Y Wang, PS Dale, AJ Conrad, P Schmid, D Garrison, C Kuo, LJ Foshag, AJ Nizze, and DL Morton |
| |
JCO Aug 1 1995: 2109–2116.
[Abstract]
[PDF]
|
|
|
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen |
| |
PJ Hesketh, T Beck, M Uhlenhopp, MG Kris, JD Hainsworth, WG Harker, JR Cohen, E Lester, JF Kessler, and D Griffen |
| |
JCO Aug 1 1995: 2117–2122.
[Abstract]
[PDF]
|
|
|
Biology and therapy of pediatric rhabdomyosarcoma |
| |
AS Pappo, DN Shapiro, WM Crist, and HM Maurer |
| |
JCO Aug 1 1995: 2123–2139.
[Abstract]
[PDF]
|
|
| Duplicate publication |
| AS Lichter |
|
JCO Aug 1 1995: 2140–2141.
[PDF]
|
|
| Neoadjuvant chemotherapy in cervix cancer: is it effective? |
| HJ Long |
|
JCO Aug 1 1995: 2141–2142.
[PDF]
|
|
| Duration of tamoxifen therapy and occurrence of endometrial cancer |
| PV Plourde and M Scott |
|
JCO Aug 1 1995: 2142.
[PDF]
|
|
| Second malignancy tumors following Hodgkin's disease in children |
| D Jenkin |
|
JCO Aug 1 1995: 2143.
[PDF]
|
|
| Effect of granulocyte colony-stimulating factor on the rate of neutrophil engraftment following peripheral-blood stem-cell transplantation |
| TR Klumpp, SL Goldberg, and KF Mangan |
|
JCO Aug 1 1995: 2144a.
[PDF]
|
|
| A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11 |
| E Goncalves, L de Costa, D Abigerges, and JP Armand |
|
JCO Aug 1 1995: 2144b–2146.
[PDF]
|
|
| Three-drug combination of cisplatin, dacarbazine, and tamoxifen in metastatic malignant melanoma |
| E Chmielowska, P Potemski, and A Pluzanska |
|
JCO Aug 1 1995: 2146–2147.
[PDF]
|
|
| Carboplatin dosimetry in renal failure |
| AP Kudelka, ZM Siddik, O Balat, and JJ Kavanagh |
|
JCO Aug 1 1995: 2147–2148.
[PDF]
|
|
